A Phase 1 interventional study of Ziftomenib and Venetoclax in Acute Myeloid Leukemia, Mixed Lineage Leukemia Gene Mutation and Refractory AML, sponsored by Kura Oncology, Inc.. Recruiting at 44 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by Kura Oncology, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing quizartinib in Leukemia, Myeloid, Acute — 6 open to participants now, 10 under way, 2 of them phase 3. quizartinib · Leukemia, Myeloid, Acute.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, this one is the 4th largest by planned enrollment, is the only one that started in 2023, is one of 8 in phase 1, and was the 24th registered.
3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →6 of the 28 studies testing quizartinib in Leukemia, Myeloid, Acute are open now, in 9 countries. Recruiting first, the newest first:
PETHEMA Foundation · Sites in Spain
Ages 18+
Daiichi Sankyo · Sites in United States, Australia, Brazil and 2 more countries
Ages 18+
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18+
Princess Maxima Center for Pediatric Oncology · Sites in Netherlands
Ages 1 mo–18 yrs
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
quizartinib: first FDA approval 2023 (VANFLYTA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 15 · Phase 3 5
First in 2007; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 420 is above the median of 40 across 3,007 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 69 across the 28 interventional studies. Of the 15 that completed or were terminated, 9 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Kura Oncology, Inc. is the lead sponsor of 18 studies on the registry; 8 are open to participants now.
Kura Oncology, Inc. has 6 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
1 of the studies testing quizartinib in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03793478Daiichi SankyoSafety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 28 studies testing quizartinib in Leukemia, Myeloid, Acute, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations.
This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in patients who have AML with certain genetic mutations. Both newly diagnosed and relapsed refractory patients with AML will be assigned to different cohorts based on specific study criteria and physician discretion.
The purpose of this study is to assess the safety, tolerability, and early signs of efficacy of ziftomenib in combination with SOC drugs to treat AML.
Key Inclusion Criteria:
Patients must have a documented NPM1 mutation or KMT2A rearrangement and have either newly diagnosed or AML
A female of must agree to use adequate as well as a double barrier method from the time of screening through 180 days following the last dose of study intervention. A male of childbearing potential must agree to use abstinence or use a double barrier method of contraception from the time of screening through 180 days following the last dose of study intervention
Key Exclusion Criteria:
Mean corrected for heart rate by Fredericia's formula (QTcF)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GVHD (graft-versus-host disease)
After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ziftomenib with Venetoclax and Azacitidine in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy
Drug: Ziftomenib · Drug: Venetoclax · Drug: Azacitidine
Ziftomenib with Venetoclax and Azacitidine in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy
Drug: Ziftomenib · Drug: Venetoclax · Drug: Azacitidine
Ziftomenib with 7+3 in newly diagnosed NPM1-m AML patients who are candidates for intensive chemotherapy and must be FLT3 wildtype or ITD ratio \<0.05
Drug: Ziftomenib · Drug: Daunorubicin · Drug: Cytarabine
Ziftomenib with 7+3 in newly diagnosed NPM1-m AML patients who are candidates for intensive chemotherapy and must be FLT3 wildtype or ITD ratio \<0.05
Drug: Ziftomenib · Drug: Daunorubicin · Drug: Cytarabine
Ziftomenib with Venetoclax in relapsed/refractory NPM1-m AML patients who have failed at least one prior line of therapy
Drug: Ziftomenib · Drug: Venetoclax
Ziftomenib with Venetoclax and Azacitidine in newly diagnosed NPM1-m AML patients
Drug: Ziftomenib · Drug: Venetoclax · Drug: Azacitidine
Ziftomenib with Venetoclax and Azacitidine in relapsed/refractory KMT2A-r AML patients who have failed at least one prior line of therapy
Drug: Ziftomenib · Drug: Venetoclax · Drug: Azacitidine
Ziftomenib with Venetoclax and Azacitidine in relapsed/refractory KMT2A-r AML patients who have failed at least one prior line of therapy
Drug: Ziftomenib · Drug: Venetoclax · Drug: Azacitidine
Ziftomenib with 7+3 in newly diagnosed KMT2A-r AML patients who are candidates for intensive chemotherapy
Drug: Ziftomenib · Drug: Daunorubicin · Drug: Cytarabine
Ziftomenib with 7+3 in newly diagnosed KMT2A-r AML patients who are candidates for intensive therapy
Drug: Ziftomenib · Drug: Daunorubicin · Drug: Cytarabine
Ziftomenib with Venetoclax and Azacitidine in newly diagnosed KMT2A-r AML patients
Drug: Ziftomenib · Drug: Venetoclax · Drug: Azacitidine
Ziftomenib with 7+3 and quizartinib in newly diagnosed NPM1-m and FLT3-ITD+ (with allelic ratio ≥0.05) AML patients who are candidates for IC and eligible to receive FLT3-targeted therapy
Drug: Ziftomenib · Drug: Daunorubicin · Drug: Cytarabine · Drug: Quizartinib
Ziftomenib with 7+3 and quizartinib in newly diagnosed NPM1-m and FLT3-ITD+ (with allelic ratio ≥0.05) AML patients who are candidates for IC and eligible to receive FLT3-targeted therapy
Drug: Ziftomenib · Drug: Daunorubicin · Drug: Cytarabine · Drug: Quizartinib
Oral Administration
Also known as: KO-539
Oral Administration
Also known as: Venclexta, Venclyxto
Subcutaneous or Intravenous Administration
Also known as: Azadine, Vidaza
Intravenous Administration
Also known as: Cerubidine, daunomycin
Intravenous Administration
Also known as: cytosine arabinoside (ara-C), Cytosar-U, Tarabine PFS
Oral Administration
Also known as: Vanflyta
Rate of dose limiting toxicities (DLTs) per dose level (Part 1a only)
Assessed by the NCI-CTCAE v5.0
Time frame: During the first 28 days of ziftomenib in combination with SOC backbone treatment (1 cycle)
Descriptive statistics of adverse events
Assessed by the NCI-CTCAE v5.0
Time frame: From Cycle 1 Day 1 up to and including 28 days following the end of 36 months of treatment
Complete remission (CR) rate
Assessed by the ELN 2022 criteria
Time frame: Until relapse, new anti-cancer therapy, death, or up to 36 months of treatment, whichever occurs first
Composite Complete Remission (CRc)
Assessed by the ELN 2022 criteria
Time frame: Until relapse, new anti-cancer therapy, death, or up to 36 months of treatment, whichever occurs first
Morphologic leukemia-free state (MLFS) rate
Assessed by the ELN 2022 criteria
Time frame: Until relapse, new anti-cancer therapy, death, or up to 36 months of treatment, whichever comes first
Measurable residual disease (MRD)
Assessed by multiparameter flow cytometry (MFC) and/or molecular analysis (NGS, PCR)
Time frame: Until relapse, new anti-cancer therapy, death, or up to 36 months of treatment, whichever occurs first
Median OS
To assess overall survival of ziftomenib
Time frame: From Cycle 1 Day 1 to date of death from any cause, assessed up to 36 months of treatment
Proportion of patients alive
To assess proportion of patients alive at 1 year following start of treatment with ziftomenib
Time frame: From Cycle 1 Day 1 until death from any cause, assessed up to 1 year following start of treatment
Median EFS
To assess median event free survival
Time frame: From Cycle 1 Day 1 to treatment failure, hematologic relapse following CR, or death from any cause, whichever comes first, assessed up to 36 months of treatment
EFS
To assess event free survival at 1 year
Time frame: From Cycle 1 Day 1 to treatment failure, hematologic relapse following CR, or death from any cause, whichever comes first, assessed up to 1 year following start of treatment
Median DOR
To assess median duration of remission
Time frame: From time of first remission to relapse or death, whichever occurs first, assessed up to 36 months from start of treatment
Proportion of patients who undergo HSCT
To assess proportion of patients who undergo hematopoietic stem cell transplant
Time frame: From Cycle 1 Day 1 until date of HSCT, assessed up to 36 months of treatment
TI
To assess rate of transfusion independence
Time frame: From 28 days prior to Cycle 1 Day 1 up to and including 28 days following the end of 36 months of treatment
Cmax
Maximum plasma concentration (Cmax) of ziftomenib and metabolites
Time frame: Cycle 1; each cycle is 28 days
Tmax
Time to maximum plasma concentration (Tmax) of ziftomenib and metabolites
Time frame: Cycle 1; each cycle is 28 days
AUC0-last
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing (AUC0-last) of ziftomenib and metabolites
Time frame: Cycle 1; each cycle is 28 days
AUCtau
Area under the concentration-time curve over a dosing interval (AUCtau) of ziftomenib
Time frame: Cycle 1; each cycle is 28 days
Accumulation ratio of ziftomenib and metabolites
To assess accumulation ratio of ziftomenib and metabolites
Time frame: Cycle 1; each cycle is 28 days
Cmax of venetoclax
Maximum plasma concentration (Cmax) of venetoclax
Time frame: Cycle 1; each cycle is 28 days
Tmax of venetoclax
Time to maximum plasma concentration (Tmax) of venetoclax
Time frame: Cycle 1; each cycle is 28 days
AUC0-last of venetoclax
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing (AUC0-last) of venetoclax
Time frame: Cycle 1; each cycle is 28 days
AUCtau of venetoclax
Area under the concentration-time curve over a dosing interval (AUCtau) of venetoclax
Time frame: Cycle 1; each cycle is 28 days
Cmax of quizartinib
Maximum plasma concentration (Cmax) of quizartinib
Time frame: Cycle 1; each cycle is 28 days
Tmax of quizartinib
Time to maximum plasma concentration (Tmax) of quizartinib
Time frame: Cycle 1; each cycle is 28 days
AUC0-last of quizartinib
Area under the concentration-time curve from time zero to the time of the last quantifiable concentration after dosing (AUC0-last) of quizartinib
Time frame: Cycle 1; each cycle is 28 days
AUCtau of quizartinib
Area under the concentration-time curve over a dosing interval (AUCtau) of quizartinib
Time frame: Cycle 1; each cycle is 28 days
Plan to share: No
Started Jul 2023 (actual). Primary completion is estimated for Apr 2030, 81 months after the start.
Of 183 industry-sponsored phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 62. This study's planned 81 months is above that.
Counting every sponsor, half of 491 studies reached it within 49 months; a quarter within 31 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Quizartinib
Kura Oncology, Inc.